Description
The US Medical Science Liaisons report shows that the future continues to look promising for Medical Science Liaison in North America, despite the disruptive forces that the Physician Payment Sunshine Act and healthcare reform presented–disruption it took pharmaceutical organizations years to assimilate. Though affected the most by these changes, it appears that Medical Affairs operations, including MSL teams, have now realigned and adapted to the new realities.
Arx Research conducted this study to uncover and present findings and KPIs on US and Canadian Medical Affairs function and the Medical Science Liaison role around:
• Organizational structures and leadership
• MSL team staffing and sizing indicators
• Key metrics on MSL activities, interactions, credentials, training and performance
• Thought Leader management, KOL target profiles
• Ten (10) MSL Team Profiles
• Budget Metrics
This US Medical Science Liaisons report presents findings from exchanges with 40 US and Canadian-based executives and MSLs representing 31 pharmaceutical organizations.
The study delivers findings to help medical affairs personnel – from management to scientific field operatives – support their decisions for assessing their operation, refining their strategy and strengthening their engagements to thought leaders.
Similar analytical research on medical science liaison operations also available for Asia-Pacific, Europe and Central/South America. Additional in-depth research on MSL training and performance metrics also available here: https://www.arxresearch.com/product-category/medical-affairs/\